Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature emphasized perioperative organ protection, neuromodulation for pain, and large pragmatic trials that refine routine choices. A biomarker‑enriched KDIGO kidney‑protection bundle reduced moderate‑to‑severe AKI after major surgery; a large multinational pediatric RCT found no renal advantage of balanced crystalloids over saline; and mechanistic plus clinical data for transcutaneous auricular vagus nerve stimulation (taVNS) mapped a circuit and showed prevention
Summary
This week’s anesthesiology literature emphasized perioperative organ protection, neuromodulation for pain, and large pragmatic trials that refine routine choices. A biomarker‑enriched KDIGO kidney‑protection bundle reduced moderate‑to‑severe AKI after major surgery; a large multinational pediatric RCT found no renal advantage of balanced crystalloids over saline; and mechanistic plus clinical data for transcutaneous auricular vagus nerve stimulation (taVNS) mapped a circuit and showed prevention of chronic postsurgical pain. These findings support targeted implementation of prevention bundles, cautious adoption of technologies informed by mechanism and RCTs, and system-level risk‑prediction approaches.
Selected Articles
1. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
In a pragmatic, multinational randomized trial across 47 emergency departments (n≈8,482 analyzed), balanced crystalloids did not reduce the composite major adverse kidney events at 30 days (MAKE30) compared with 0.9% saline in children with suspected septic shock. Hospital‑free days were similar, though balanced fluids produced lower rates of hyperchloremia and hypernatremia while hyperlactatemia was slightly more frequent.
Impact: Provides definitive, high‑quality evidence that balanced crystalloids do not reduce short‑term renal composite outcomes versus saline in pediatric septic shock, clarifying a major clinical question and informing fluid selection policies.
Clinical Implications: Either balanced fluids or 0.9% saline are reasonable for initial resuscitation in pediatric septic shock with attention to electrolyte profiles; balanced crystalloids may be preferred when avoiding hyperchloremia/hypernatremia is important, while monitoring lactate trends.
Key Findings
- MAKE30: 3.4% (balanced) vs 3.0% (saline); risk ratio 1.10 (95% CI 0.88–1.40; P=0.85).
- Median hospital‑free days (28‑day window) identical (median 23).
- Electrolyte differences: hyperchloremia 31.4% (balanced) vs 49.0% (saline); hypernatremia 1.8% vs 3.1%; hyperlactatemia 19.8% vs 16.7%.
2. Auricular vagus nerve stimulation drives analgesia via an auricle-brain axis in a mouse model of neuropathic pain.
Preclinical multimodal experiments map an auricle‑to‑brain circuit (jugular‑nodose ganglia → NTS pro‑opiomelanocortinergic neurons → vlPAG glutamatergic neurons) mediating taVNS analgesia in neuropathic pain mice; optogenetic activation recapitulates and chemogenetic silencing abolishes effect. The work provides causal circuit evidence to guide translational parameter optimization for taVNS.
Impact: Provides first‑class mechanistic, causal circuit mapping for taVNS analgesia—an essential translational step that rationalizes electrode placement, targets, and biomarkers to advance human trials.
Clinical Implications: Although preclinical, the identified JNG→NTS→vlPAG axis supports targeted taVNS parameter exploration in early human trials for perioperative and neuropathic pain, and suggests candidate biomarkers (brainstem/PAG engagement) for responder stratification.
Key Findings
- taVNS produces robust analgesia in a neuropathic pain mouse model.
- Identified circuit: jugular‑nodose ganglia → NTS (POMC neurons) → vlPAG glutamatergic neurons.
- Optogenetic activation at multiple nodes mimics taVNS analgesia; chemogenetic silencing abolishes it.
3. Implementation of a kidney protection strategy to prevent acute kidney injury after major surgery in high-risk patients identified by biomarkers: a systematic review and individual participant data meta-analysis of randomized controlled trials.
An IPD meta‑analysis pooling four RCTs (n=1,851) found that a KDIGO‑based kidney protection bundle applied to biomarker‑enriched high‑risk surgical patients reduced moderate‑to‑severe AKI within 72 hours (KDIGO stage ≥2; OR 0.55, 95% CI 0.44–0.70) without heterogeneity. The bundle combined hemodynamic and fluid optimization, nephrotoxin avoidance, frequent renal monitoring, and glycemic control.
Impact: High‑level IPD evidence that a standardized perioperative kidney protection bundle prevents clinically meaningful AKI in biomarker‑identified high‑risk patients, offering an implementable strategy to reduce postoperative kidney injury.
Clinical Implications: Integrate KDIGO‑based kidney protection bundles into perioperative pathways for biomarker‑identified high‑risk patients (hemodynamic targets, nephrotoxin stewardship, frequent renal labs, glucose control) and prioritize pragmatic multicenter implementation studies.
Key Findings
- KDIGO stage ≥2 AKI within 72 h reduced with bundle: OR 0.55 (95% CI 0.44–0.70; p<0.0001).
- No statistical heterogeneity across included trials.
- Bundle components: hemodynamic/fluid optimization, nephrotoxin avoidance, renal monitoring, glycemic control.